389 related articles for article (PubMed ID: 35774424)
21. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G; Remon J; Hendriks LEL; García-Campelo R; Rolfo C; Van Schil P; Forde PM; Besse B; Subbiah V; Reck M; Soria JC; Peters S
Nat Rev Clin Oncol; 2023 Oct; 20(10):664-677. PubMed ID: 37488229
[TBL] [Abstract][Full Text] [Related]
22. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward.
Shinada K; Murakami S
Onco Targets Ther; 2023; 16():99-108. PubMed ID: 36814961
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
25. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.
Pradhan M; Chocry M; Gibbons DL; Sepesi B; Cascone T
Transl Lung Cancer Res; 2021 Jan; 10(1):590-606. PubMed ID: 33569339
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
28. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Qi C; Tian P; Li W
Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
[TBL] [Abstract][Full Text] [Related]
29. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
Gentzler RD; Riley DO; Martin LW
Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
[TBL] [Abstract][Full Text] [Related]
30. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.
Friedlaender A; Naidoo J; Banna GL; Metro G; Forde P; Addeo A
Cancer Treat Rev; 2022 Mar; 104():102350. PubMed ID: 35093800
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC).
Wang Q; Qi C; Luo J; Xu N; Xu MT; Qiang Y; Zhang C; Shen Y
Front Oncol; 2023; 13():1239451. PubMed ID: 38205138
[TBL] [Abstract][Full Text] [Related]
32. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
Mielgo-Rubio X; Montemuiño S; Jiménez U; Luna J; Cardeña A; Mezquita L; Martín M; Couñago F
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638296
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Chen LN; Wei AZ; Shu CA
Ther Adv Med Oncol; 2023; 15():17588359231163798. PubMed ID: 37007633
[TBL] [Abstract][Full Text] [Related]
35. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
Xu Z; Zou Z; Hao X; Xing P; Li J
Cancer Innov; 2023 Feb; 2(1):65-78. PubMed ID: 38090369
[TBL] [Abstract][Full Text] [Related]
37. Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.
Rojas F; Parra ER; Wistuba II; Haymaker C; Solis Soto LM
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681755
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Xie H; Shi X; Wang G
Am J Cancer Res; 2021; 11(6):2521-2536. PubMed ID: 34249414
[TBL] [Abstract][Full Text] [Related]
39. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
J Oncol Pharm Pract; 2024 Jun; ():10781552241260864. PubMed ID: 38860323
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
Shukla N; Hanna N
Lung Cancer (Auckl); 2021; 12():51-60. PubMed ID: 34234606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
